Yoshio Tomizawa

Randomized Phase III Trial of Erlotinib Versus Docetaxel As Second- or Third-Line Therapy in Patients With Advanced Non–Small-Cell Lung Cancer: Docetaxel and Erlotinib Lung Cancer Trial (DELTA)

Tomoya Kawaguchi, Masahiko Ando, Kazuhiro Asami et al. · Journal of Clinical Oncology · 2014 · 263 citations · Full text

Medicine, Oncology, Pharmacology +16

Inhibition of lung cancer cell growth and induction of apoptosis after reexpression of 3p21.3 candidate tumor suppressor gene <i>SEMA3B</i>

Yoshio Tomizawa, Yoshitaka Sekido, Masashi Kondo et al. · Proceedings of the National Academy of Sciences · 2001 · 209 citations · Full text

Medicine, Genetics, Oncology +12

ASC amino-acid transporter 2 (ASCT2) as a novel prognostic marker in non-small cell lung cancer

Kimihiro Shimizu, Kyoichi Kaira, Yoshio Tomizawa et al. · British Journal of Cancer · 2014 · 134 citations · Full text

Medicine, Cancer Biology, Oncology +13

Clinicopathologic Significance of the Mutations of the<i>Epidermal Growth Factor Receptor</i>Gene in Patients with Non–Small Cell Lung Cancer

Yoshio Tomizawa, Hironobu Iijima, Noriaki Sunaga et al. · Clinical Cancer Research · 2005 · 130 citations · Full text

Medicine, Genetics, Oncology +14

Phase II prospective study of the efficacy of gefitinib for the treatment of stage III/IV non-small cell lung cancer with EGFR mutations, irrespective of previous chemotherapy

Noriaki Sunaga, Yoshio Tomizawa, Noriko Yanagitani et al. · Lung Cancer · 2007 · 129 citations

Medicine, Oncology, Pharmacology +16